Research
Hormonal
Adding Thiazolidinediones (TZDs) to metformin has the most significant influence on lipid levels (specifically lowering LDL and improving lipid profiles) in women with PCOS.
If lipid management is a primary concern in your PCOS treatment, adding a TZD (like pioglitazone) to metformin is the most effective strategy among the reviewed drugs for improving your lipid profile.
ModerateSupportsMEDIUM confidence
while thiazolidinediones (TZDs) had the most influence on lipid levels.
Why this rating
Systematic review of 16 RCTs, heterogeneity prevented meta-analysis.
Source
Comparative Effectiveness of Antidiabetic Drugs as an Additional Therapy to Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review of Metabolic Approaches
Maryam Heidarpour et al. · International Journal of Endocrinology · 2024
DOI 10.1155/2024/9900213
systematic_review · n=878Cited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Adding DPP4 inhibitors (e.g., sitagliptin) to metformin significantly improves glycemic profiles (fasting blood sugar and HOMA-IR) in women with PCOS compared to metformin alone.Moderate
- Adding GLP-1 receptor agonists (GLP1RAs) to metformin effectively improves anthropometric measures (weight, BMI, waist circumference, waist-to-hip ratio) in women with PCOS.Moderate
- None of the combined antidiabetic therapies (DPP4i, GLP1RA, TZD, SGLT2i) showed a significant change in blood pressure compared to metformin alone in women with PCOS.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →